South America Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Condition Type (Primary Lymphedema and Secondary Lymphedema), Treatment Type (Laser Therapy, Compression Devices and Bandaging, Drug Therapy, Physiologic

South America Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Condition Type (Primary Lymphedema and Secondary Lymphedema), Treatment Type (Laser Therapy, Compression Devices and Bandaging, Drug Therapy, Physiological Procedures {Lymphovenous Anastomosis (LVA) and Vascularized Lymph Node Transfer (VLNT)}, Debulking Procedures {Surgical Debulking, Liposuction, and Others}, and Others), and End User (Hospitals, Clinics, Clinical Research Organizations, and Others) 

The lymphedema treatment market in SAM is expected to grow from US$ 300.85 million in 2021 to US$ 419.04 million by 2028; it is estimated to grow at a CAGR of 4.8% from 2021 to 2028. The utility of robotics for lymphatic surgery allows much greater flexibility and precision compared to previously used laparoscopy. Additionally, the use of robotics proves optimal for both surgeon and patient outcomes and will reveal positive results during the forecast period. For instance, patients who underwent the single-robotic surgery for lymphedema in May 2020 have provided positive anecdotal feedback, including significant clinical improvement such as the ability to wear clothes with the surgeon's significant accomplishments. Further, robots enabled with artificial intelligence (AI) are increasingly assisting in microsurgical procedures in lymphedema surgeries for reducing surgeon variations that could affect patient recovery. For example, for lymphedema surgery, in May 2020, an urogynecology surgeon performed a first-of-its-kind single-port robotic mental harvest by utilizing a free lymph node transfer, intended for minimally invasive surgical treatment of lymphedema. The main objective of this new surgical treatment method is to minimize donor site morbidity with debilitating lymphedema symptoms, so growing use of robotics is expected to fuel the market growth.

Based on end-user, the hospitals segment led the SAM lymphedema treatment market in 2020. The hospital segment accounted for the maximum share of the lymphedema treatment market due to the growing adoption of minimally invasive surgeries in hospitals and the uptake of advanced imaging modalities for treating lymphedema. Additionally, surgeries are performed in hospitals for treating lymphedema. Furthermore, favorable reimbursement policies supporting lymphatic treatment in hospitals support the overall market growth. For instance, growing awareness of lymphedema as an expensive preventable complication following oncology surgery eliminates barriers between the medical coverage for therapeutic and prophylactic procedures. among patients, hospitals, and the healthcare systems experienced lucrative benefits.

The COVID-19 pandemic situation subsequently resulted in the delay in spreading adequate awareness programs in the SAM region. The COVID-19 pandemic has not only resulted in millions of deaths but also posed indirect effects on other diseases and healthcare programs. In view of the COVID-19 pandemic and the need to maintain social distancing, government organizations issued the recommendation on 1st April 2020 to put all community-based surveys, active case-finding activities, and mass treatment campaigns for neglected tropical diseases on hold until further notice. However, as the cases of lymphedema treatment were rising in the region, government bodies bought the concept of telemedicine through which the awareness programs could reach the people suffering from lymphedema in Brazil and Argentina and help them in mitigating such risks. However, healthcare investments in Brazil and proper regulations are expected to positively impact the lymphedema treatment market in Brazil and Argentina.

The overall SAM lymphedema treatment market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining an overview and forecast of the SAM lymphedema treatment market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data and to gain more analytical insights into the topic. The participants typically involved in this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers—along with external consultants such as valuation experts, research analysts, and key opinion leaders—specializing in the SAM lymphedema treatment market. 3M Company, BSN medical GmbH, Huntleigh Healthcare Limited, Lohmann & Rauscher GmbH & Co. KG, Mego Afek ltd, Sigvaris Group, and Smith & Nephew are a few key players operating in the market in this region.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the SAM lymphedema treatment market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the SAM lymphedema treatment market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the lymphedema treatment market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution